2seventy bio (NASDAQ:TSVT) Stock, Quote.Headers.trade-ideas

2seventy bio

2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment, focusing on researching, developing and commercializing potentially transformative treatments for cancer.

TSVT

Biotech

Large Cap

News

Health Care

Movers

General

2seventy Bio finalized an asset purchase agreement with Novo Nordisk involving the Hemophilia A program and in vivo gene editing technology. The 2seventy bio team will join Novo Nordisk, focusing on advancing the technology.

Novo Nordisk Buys 2seventy&#39;s Hemophilia A Program, Divestiture Supports Exclusive Focus On Abecma

FDA Shutterstock

Penny Stocks

GILD

LEGN

Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings—the highest safety-rel

FDA Mandates &#34;Boxed Warning&#34; For Bristol Myers, Johnson &amp; Johnson CAR-T-Based Blood Cancer Therapies

BristolMeyersSquibb.Courtesyof.02-LVL-Exterior-Sign-101520-media

FDA approves Bristol-Myers Squibb and 2seventy Bio Abecma (ide-cel) for relapsed or refractory multiple myeloma after ≥2 prior therapies. Extends progression-free survival by 13.3 months vs. standard care.

FDA Approves Bristol-Myers/2seventy Bio&#39;s Abecma For Earlier Use In Pretreated Blood Cancer Patients With Updated Boxed Warning On Secondary Cancer

2seventy bio Inc

Roth MKM analyst Scott Fortune initiates coverage on Turning Point Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPB#NYSE">TPB</a>) with a Buy rating and announces Price Target of $50.

Price Target

Initiation

Analyst Ratings

Roth MKM Initiates Coverage On Turning Point Brands with Buy Rating, Announces Price Target of $50

Larimar Therapeutics, Inc. - Common Stock

LRMR

Larimar Therapeutics Announced That Data From Its Nomlabofusp Phase 1 Studies And Phase 2 Dose Exploration Study, Some Of Which Has Been Previously Disclosed, Will Be Presented At The Annual International Congress For Ataxia Research

HC Wainwright &amp; Co. analyst Robert Burns upgrades Prelude Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRLD#NASDAQ">PRLD</a>) from Neutral to Buy and announces $5 price target.

Upgrades

PRLD

HC Wainwright & Co. Upgrades Prelude Therapeutics to Buy, Announces $5 Price Target

B. Riley Securities analyst Madison El-Saadi initiates coverage on WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) with a Buy rating and announces Price Target of $11.

B. Riley Securities Initiates Coverage On WAVE Life Sciences with Buy Rating, Announces Price Target of $11

Commodities

Legal

Markets

TUSK

Cobra Acquisitions, A Subsidiary Of Mammoth Energy Services, Announced That The Previously Disclosed Settlement Agreement With The Puerto Rico Electric Power Authority Was Approved By The Title III Court, PREPA Required To Pay Cobra $150M Within Ten Business Days

<ul>
<li>One program aims to identify novel Aramchol-based drug combinations to overcome resistance to standard-of-care oncological treatments for patients with advanced colorectal and hepatic cancers.&nbsp;</li>
<li>Another program aims to unravel new mechanisms of action that will allow the development of a novel Aramchol-based drug combination targeting cardiac fibrosis, or scarring of the heart, which occurs in many cardiovascular diseases that can lead to heart dysfunction and failure.&nbsp;</li>
<li>The Company plans on releasing new data from in-vitro and ex-vivo studies in these programs during the fourth quarter of 2024.</li>
</ul>

GLMD

Galmed Pharmaceuticals Plans To Broaden Its Drug Development Activities, Consisting Of Two Additional Programs Over The Next Two Years

B. Riley Securities initiates coverage on Centessa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTA#NASDAQ">CNTA</a>) with a Buy rating and announces Price Target of $33.

CNTA

B. Riley Securities Initiates Coverage On Centessa Pharmaceuticals with Buy Rating, Announces Price Target of $33

COEP

Coeptis Therapeutics Receives Notification Letter From Nasdaq Hearings Panel Granting Its Request For Continued Listing Through January 15, 2025

SYTA

Siyata Mobile Announced That Its SD7 Handsets And VK7 Vehicle Kits Were Purchased And Deployed By A New Customer, Trans-west Security Systems

Raymond James analyst Stephen Laws upgrades Safehold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAFE#NYSE">SAFE</a>) from Market Perform to Outperform and announces $34 price target.

SAFE

Raymond James Upgrades Safehold to Outperform, Announces $34 Price Target

SpaceX CEO Elon Musk said on Thursday that the rocket manufacturing company intends to <a href="https://www.benzinga.com/news/24/07/39567836/spacex-ceo-elon-musk-picks-terminus-for-mars-first-starship-enabled-city-after-just-4-test-flights">offer a trip to Mars</a> to anyone who volunteers in the future but warned that the journey might be uncomfortable.
What Happened: &#8220;In all seriousness, SpaceX hopes to offer travel to Mars to anyone who wants to go&#8230;&#8221; Musk wrote on social media platform X in response to former European Union Commissioner Thierry Breton with whom he has a history of sparring now and then.
However, the journey to Mars, Musk warned, will be like a &#8220;long sea voyage.&#8221;
&#8220;&#8230;.it will be like a long sea voyage in centuries past – dangerous and uncomfortable, but great adventure!&#8221; Musk said.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">In all seriousness, SpaceX hopes to offer travel to Mars to anyone who wants to go, bearing in mind that it will be like a long sea voyage in centuries past – dangerous and uncomfortable, but great adventure! Becoming multiplanetary ensures the long-term survival of life.
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1836705091446853687?ref_src=twsrc%5Etfw">September 19, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Musk aims to take humans to Mars with SpaceX&#8217;s Starship launch vehicle in an attempt to &#8220;make life multi-planetary.&#8221; Musk has previously even envisioned a self-sustaining city on Mars called Terminus.
Why It Matters: Earlier this month, Musk said the first Starships will <a href="https://www.benzinga.com/news/24/07/39567836/spacex-ceo-elon-musk-picks-terminus-for-mars-first-starship-enabled-city-after-just-4-test-flights" target="_blank" rel="noreferrer noopener">head to Mars in two years</a> once the next Earth-Mars transfer window opens.
The first launches to Mars in 2026, Musk then said, will not have a crew onboard and will be aimed at testing the flight's ability to land intact on Mars.
"If those landings go well, then the first crewed flights to Mars will be in 4 years," Musk wrote, pegging the first crewed Starship flights to the neighboring planet for 2028. A self-sustaining city, he said, should be ready in about 20 years. 
Starship, however, is still under development and undergoing test flights. It was last launched in June and the company is <a href="https://www.benzinga.com/news/24/09/40932353/spacex-continues-to-prepare-for-future-starship-flights-despite-delays-in-faa-launch-clearance-elon">now awaiting the green light </a>from the Federal Aviation Administration for its fifth flight test. 
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link</a>.
Read More:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40934031/teamsters-opts-to-not-endorse-either-harris-or-trump-for-upcoming-presidential-elections-citing-fail">Teamsters Opts To Not Endorse Either Harris Or Trump For Upcoming Presidential Elections, Citing Failure To Secure Pledges Of Non-Interference In Union Campaigns</a></li>
</ul>
Image generated using Midjourney and official SpaceX photos on Flickr

SPACE

Tech

SpaceX CEO Elon Musk Says Anyone Can Go To Mars With SpaceX But Journey Would Be Like A 'Long Sea Voyage In Centuries Past'

HC Wainwright &amp; Co. analyst Arthur He reiterates Satellos Bioscience (TSX:<a class="ticker" href="https://www.benzinga.com/stock/MSCL#TSX">MSCL</a>) with a Buy and maintains C$1.2 price target.

Reiteration

TSX:MSCL

HC Wainwright & Co. Reiterates Buy on Satellos Bioscience, Maintains C$1.2 Price Target

ADI-001 demonstrated robust tissue trafficking resulting in high levels of ADI-001, significant chimeric antigen receptor (CAR) T cell activation, and complete CD19+ B cell depletion in secondary lymphoid tissue.&nbsp;

ACET

Adicet Bio Announced ADI-001 Clinical Biomarker Data From The Phase 1 GLEAN Trial Which Further Reinforces The Potential Of ADI-001 As Allogeneic Cell Therapy For Autoimmune Diseases

Offerings

Murphy Oil Intends To Offer $600M Of Senior Notes Due 2032

Ahead of the 2024 presidential election, Elon Musk has thrown his support behind Donald Trump, while his employees are reportedly largely backing Kamala Harris, according to recent data.
What Happened: According to OpenSecrets, employees at Tesla Inc. have contributed $42,824 to Harris&#8217; campaign, compared to $24,840 for Trump. Workers at SpaceX have donated $34,526 to Harris, while only $7,652 has gone to Trump. At X, formerly Twitter, employees have given $13,213 to Harris and less than $500 to Trump, Reuters reported on Thursday.
These figures, though relatively small, highlight a political divide between Musk and his workforce. Musk, the world&#8217;s richest man, has promoted Trump on X and criticized left-leaning ideologies as a &#8220;woke-mind virus.&#8221; He did not respond to requests for comment. In 2020, Musk supported President Joe Biden but has since shifted rightward.
Trump has promised to appoint Musk to lead a government efficiency commission if he wins the Nov. 5 election. The OpenSecrets data includes donations from employees, owners, and their immediate family members, as companies themselves cannot donate to federal campaigns.
See Also: <a href="https://www.benzinga.com/news/24/09/40899012/elon-musk-reacts-after-trump-campaign-releases-over-50-examples-of-democrats-rhetoric-that-inspired?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Reacts After Trump Campaign Releases Over 50 Examples of Democrats&#8217; Rhetoric That &#8216;Inspired Assassination Attempt&#8217;</a>
Many of Musk&#8217;s employees are based in California, a Democratic stronghold, noted Ross Gerber, CEO of Gerber Kawasaki Wealth and Investment Management, a Tesla shareholder and X investor. In July, Musk announced plans to move X and SpaceX headquarters to Texas due to a California gender-identity law, which he called the &#8220;last straw.&#8221; 
Tesla and X have yet to respond to Benzinga&#8217;s queries.
Why It Matters: Musk&#8217;s political stance has evolved significantly over the years. In August, Musk explained his <a href="https://www.benzinga.com/news/24/08/40329702/elon-musk-who-once-queued-for-6-hours-to-shake-obamas-hand-explains-why-hes-now-supporting-trump-my">support for Trump</a>, stating that his track record has been moderate and he has not been particularly political in the past. He revealed this during a conversation with Trump, touching on various topics from immigration to electric vehicles. 
In September, Musk commented on a debate between Trump and Harris, expressing <a href="https://www.benzinga.com/news/24/09/40808912/elon-musk-says-kamala-harris-exceeded-most-peoples-expectations-but-debate-hosts-were-unfair-to-trum">dissatisfaction with the debate hosts</a> and raising concerns about the lack of discussion on the national debt crisis. He also mentioned that Harris exceeded most people&#8217;s expectations during the debate.
Recently, Musk faced backlash for a <a href="https://www.benzinga.com/news/24/09/40890277/elon-musk-says-his-now-deleted-controversial-post-after-latest-trump-assassination-which-was-labeled">controversial post on X</a>, which he later deleted. The post questioned why no one was attempting to assassinate President Joe Biden or Harris, following an assassination attempt on Trump. The White House labeled the post as &#8220;irresponsible.&#8221;
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40917216/elon-musk-says-warren-buffett-is-positioning-for-kamala-harris-win-with-his-277b-cash-pile-as-pr?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Says Warren Buffett Is Positioning For Kamala Harris Win With His $277B Cash Pile As Pro-Trumper John Paulson Warns Of Equity Market Exit</a></li>
</ul>
Image via Shutterstock
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

TSLA

While Elon Musk Backs Trump For The White House, His Teams At Tesla, X And SpaceX Are Supporting Kamala Harris: Employees Have Reportedly Donated Over $90K To Vice President's Campaign

Raymond James analyst Stephen Laws downgrades NexPoint Real Est Finance (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NREF#NYSE">NREF</a>) from Strong Buy to Market Perform.

Downgrades

NREF

Raymond James Downgrades NexPoint Real Est Finance to Market Perform

This significant grant will fund a key research study over the next several years, advancing preclinical and ultimately, clinical studies of intranasal anti-CD3 as a potential treatment for this devastating neurodegenerative condition.

Financing

TLSA

Tiziana Life Sciences Announced The National Institutes Of Health Have Awarded A $4M Grant To Study Nasal Anti-CD3 For Alzheimer's Disease

Confirmed overall response rate (ORR) was&nbsp;37.5%&nbsp;for pelareorep + paclitaxel and&nbsp;13.3%&nbsp;for paclitaxel.&nbsp;As previously reported, ORRs at week 16 (the trial&#39;s primary endpoint) in the pelareorep + paclitaxel and paclitaxel monotherapy cohorts were&nbsp;31%&nbsp;and&nbsp;20%, respectively.
&quot;The fact that the median overall survival was not reached because more than half the patients were still alive at the end of the study is a remarkable achievement for us,&quot; said&nbsp;Wayne Pisano, Interim CEO and Chair of Oncolytics&#39; Board of Directors.
&nbsp;

ONCY

Oncolytics Reports Clinical Results From BRACELET-1 Study; Says Overall Survival Results Corroborate Results Of Previous Randomized IND-213 Breast Cancer Study

Raymond James analyst Stephen Laws downgrades Lument Finance Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LFT#NYSE">LFT</a>) from Outperform to Market Perform.

Raymond James Downgrades Lument Finance Trust to Market Perform

SLRN

Acelyrin Announced That Results From Its Global Phase 3 Trial Of Izokibep In Moderate-to-severe Hidradenitis Suppurativa Patients Will Be Shared At The 2024 European Academy Of Dermatology And Venereology

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
No matter your investing style, we all hope to find overlooked stock gems. These are where the biggest gains are made. But finding these stocks can be a challenge. Having access to information investors could only have dreamt of 30 years ago is a double-edged sword. It can be difficult to distinguish between hidden gems and hyped-up junk.



At times like these, it can be useful to follow analyst sentiment. But, by definition, overlooked stocks are stocks that either analysts ignore, or they&rsquo;ve turned negative on for the wrong reason(s). For this article, I&rsquo;m looking at stocks that one or more analysts have downgraded or lowered their price target in the last 60 days.



Analysts frequently think short-term. Buying the rumor and selling the news is common among this group. However, if you play the long game and you have a suitable risk tolerance, you can find overlooked stock gems like the three listed below.



<h2>Pure Storage (PSTG)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/pstg-1600-300x169.png" alt="The Pure Storage logo at the entrance to its office in Mountain View, California. PSTG stock."><div>Source: Tada Images / Shutterstock</div></div>Pure Storage (NYSE:<a href="https://investorplace.com/stock-quotes/pstg-stock-quote/">PSTG</a>) may seem to be an odd choice for a list of overlooked stock gems. The PSTG stock price is up 73% in the last 12 months and 81% in 2024. That would make the stock <a href="https://investorplace.com/2024/07/time-to-exit-3-tech-stocks-flashing-warning-signs/" target="_blank">more likely to be overvalued</a> than undervalued. And that&rsquo;s what the analysts seem to believe.



The company reported a solid earnings report with year-over-year gains on the top and bottom lines. But, in a similar vein to Palantir Technologies (NYSE:<a href="https://investorplace.com/stock-quotes/pltr-stock-quote/">PLTR</a>), some analysts believe the growth is not enough to justify further stock price growth. In the last 30 days, Morgan Stanley (NYSE:<a href="https://investorplace.com/stock-quotes/ms-stock-quote/">MS</a>) and UBS Group (NYSE:<a href="https://investorplace.com/stock-quotes/ubs-stock-quote/">UBS</a>) have downgraded the stock, with UBS giving the stock a rare Sell rating.



The belief is that Pure Storage will have a hard time growing at the aggressive pace needed to justify its valuation. Adding to that concern is the growing competition in the data center space that the company occupies.



Nevertheless, analysts are <a href="https://www.tradingview.com/symbols/NYSE-PSTG/forecast/" target="_blank">generally bullish</a> on the PSTG stock and have a consensus price target of 9% higher than its current price.&nbsp;



<h2>Paramount Global (PARA)</h2>



<a href="https://investorplace.com/wp-content/uploads/2024/05/paramount.png"><img width="300" height="152" src="https://investorplace.com/wp-content/uploads/2024/05/paramount-300x152.png" alt="Paramount Global (PARA) - Analyst Downgrades"></a>It&rsquo;s always cause for concern when analysts initiate their coverage with a Sell rating. However, that&rsquo;s exactly what happened to Paramount Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/para-stock-quote/">PARA</a>). On June 25, Goldman Sachs (NYSE:<a href="https://investorplace.com/stock-quotes/gs-stock-quote/">GS</a>) initiated coverage on PARA stock with a Sell <a href="https://www.marketbeat.com/instant-alerts/nasdaq-para-options-data-report-2024-07-03/#google_vignette">rating</a> and a $9.50 price target. That comes after Wells Fargo (NYSE:<a href="https://investorplace.com/stock-quotes/wfc-stock-quote/">WFC</a>) downgraded PARA stock to Underweight and slapped a $9 price tag on the stock.



The issues surrounding Paramount are well-known to anyone following the stock. In the game of musical chairs that is happening in the streaming industry, the company is left without a chair. It can&rsquo;t find a buyer. The most public rebuke came as talks of merging with its majority shareholder, Skydance, fell through.



But that may be changing. PARA stock is moving higher on news that the <a href="https://investorplace.com/2024/07/paramount-para-stock-climbs-as-merger-deal-nears-finish-line/" target="_blank">merger is back on.</a> There are still many obstacles to clear, but if Paramount has a viable place in the streaming landscape, it may become one of the overlooked stock gems of 2024.



<h2>2seventy bio (TSVT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/10/lab-300x169.jpg" alt="Scientists in a lab"><div>Source: Matej Kastelic / Shutterstock</div></div>If you&rsquo;re looking for overlooked stock gems, <a href="https://investorplace.com/stock-types/penny-stocks/">penny stocks</a> are a good place to start. That&rsquo;s the case for 2seventy bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/tsvt-stock-quote/">TSVT</a>). The cell and gene therapy company has just a $206 million market cap, but it has revenue &mdash; which is something many companies its size cannot claim.



In this case, the company received FDA approval for Abecma. It&rsquo;s a cellular therapy for advanced-stage multiple myeloma patients. The company developed the therapy as part of its collaboration with Bristol Myers Squibb (NYSE:<a href="https://investorplace.com/stock-quotes/bmy-stock-quote/">BMY</a>). Better still, 2seventy bio recently received an <a href="https://ir.2seventybio.com/news-releases/news-release-details/us-fda-approves-bristol-myers-squibb-and-2seventy-bios-abecma" target="_blank">expanded label for Abecma</a> that may increase revenue.&nbsp;



That hasn&rsquo;t been enough to placate at least one analyst. On June 6, Goldman Sachs downgraded TSVT stock from a Neutral to a Sell with a new price target of $2. And even with Wedbush maintaining its Neutral rating, analysts only give the stock a $5 price target.&nbsp;



This isn&rsquo;t unique for a company that is unprofitable at a time when interest rates remain high. But continued progress towards profitability combined with a rate cut may be enough to make these downgrades look overdone.



On the date of publication, Chris Markoch had a long position in PLTR. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines.</a>



On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.
<div>Chris Markoch is a freelance financial copywriter who has been covering the market for over five years. He has been writing for InvestorPlace since 2019.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/07/3-hidden-stock-gems-that-wall-street-is-overlooking/">3 Hidden Stock Gems That Wall Street Is Overlooking</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

3 Hidden Stock Gems That Wall Street Is Overlooking

2seventy bio's Abecma: Compelling Investment In Multiple Myeloma Despite Competition

Legend Biotech surges amid takeover speculation (update)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on 2seventy bio (TSVT – Research Report) and Abbott L...

Analysts Offer Insights on Healthcare Companies: 2seventy bio (TSVT) and Abbott Laboratories (ABT)

2seventy bio GAAP EPS of $0.45, revenue of $8.96M

TD Cowen analyst Yaron Werber has maintained their neutral stance on TSVT stock, giving a Hold rating on July 29. Yaron Werber has given his Hold r...

Hold Rating on 2seventy bio: Balancing Modest Sales Growth Against Competitive Market Pressures

In a report released on August 7, Daina Graybosch from Leerink Partners maintained a Buy rating on 2seventy bio (TSVT – Research Report). The compa...

Leerink Partners Keeps Their Buy Rating on 2seventy bio (TSVT)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on 2seventy bio (TSVT – Research Report), Illumina (ILM...

Analysts Offer Insights on Healthcare Companies: 2seventy bio (TSVT), Illumina (ILMN) and Larimar Therapeutics (LRMR)

2seventy bio, Inc. (TSVT) Q2 2024 Earnings Call Transcript

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Walgreens Boots Alliance (WBA – Research Report), 2seventy bio (T...

Analysts' Opinions Are Mixed on These Healthcare Stocks: Walgreens Boots Alliance (WBA), 2seventy bio (TSVT) and Repare Therapeutics (RPTX)

BMYMP

ILMN

PARA

PLTR

PSTG

REGN

RPTX

Press Releases

2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors

2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron

U.S. FDA Approves Bristol Myers Squibb and 2seventy bio's Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy

2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024

2seventy bio Reports First Quarter Financial Results and Recent Operational Progress

2seventy bio to Participate in Upcoming Investor Conferences

2seventy bio Announces Sale of Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to Novo Nordisk for up to $40 million

2seventy bio to Report Second Quarter 2024 Financial Results on August 7, 2024

2seventy bio Reports Second Quarter Financial Results and Recent Operational Progress

2seventy bio to Participate in the 2024 Morgan Stanley Global Healthcare Conference

Abeona Therapeutics

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune Therapeutics

Amarin Corporation plc - American Depositary Shares, each representing one Ordinary Share

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

2seventy bio

2seventy bio (TSVT) Forecast

2seventy bio (NASDAQ:TSVT) Stock, Quote.Headers.trade-ideas